ArticleThe Journal of infectious diseases2025
Use of an Ethinyl Estradiol/Etonogestrel Vaginal Ring Alters Vaginal Microbial Communities in Women With HIV.
Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Preclinical Toxicological evaluation of the HIV entry inhibitor peptide 2P23 as a candidate rectovaginal microbicide.Scientific reports · 2026Article
- The female microbiome in HIV prevention, pathogenesis, and treatment.Current opinion in HIV and AIDS · 2026Review
- Lactic acid produced by optimal vaginal Lactobacillus spp. potently and specifically inactivates HIV-1 in vitro by targeting the viral RNA genome and reverse transcriptase.PLoS pathogens · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundHuman immunodeficiency virus 1 (HIV-1) antiretroviral therapy (ART) alters hormonal contraceptive levels delivered via intravaginal ring (IVR) in a regimen-specific manner. We explored the role of the IVR on vaginal microbial communities, vaginal short chain fatty acids (SCFAs), vaginal HIV shedding, and the effect of vaginal microbes on hormone concentrations in cisgender women with HIV (WWH).
methodsVaginal microbes were assessed by 16S RNA sequencing of weekly vaginal swabs, vaginal SCFA by mass spectrometry, HIV-1 shedding by nucleic acid amplification on vaginal aspirates, and bacterial vaginosis by Nugent scoring from 74 participants receiving an etonogestrel/ethinyl estradiol (ENG/EE) intravaginal ring while on no ART (n = 25), efavirenz-based ART (n = 25), or atazanavir-based ART (n = 24).
resultsAt baseline, microbial communities of the 64 substudy eligible participants robustly classified as Lactobacillus crispatus-dominant (n = 8), Lactobacillus gasseri-dominant (n = 2), Lactobacillus iners-dominant (n = 17), or mixed anaerobic communities (n = 37). During IVR therapy, there was an increased probability of Lactobacillus-dominant community state types (CSTs) (odds ratio = 1.61, P = .04). Vaginal CSTs were associated with Nugent scores. Bacterial vaginosis-associated bacteria were associated with significantly higher and L. iners with lower Nugent scores (all P adjusted <.1). Lactic acid levels were correlated with the relative abundance of Lactobacillus species (r2 = 0.574; P < .001). Vaginal shedding of HIV-1 was less common in women with L. crispatus-dominant microbiomes (P = .04). Mixed anaerobic vaginal communities modulated EE concentrations in a regimen-specific manner.
conclusionsCombined ENG/EE IVR therapy was associated with an increase in Lactobacillus-dominant vaginal microbial communities in WWH and may benefit those with bacterial vaginosis. EE levels were altered by the vaginal microbiota.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.